Retatrutide, a experimental dual agonist of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) receptor , is demonstrating promising data in early clinical studies. Current research https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/